Condition: Advanced Solid Tumours · Small Cell Lung Cancer · Sponsor: Impact Therapeutics, Inc.
This is an open-label, multi-center, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, PK characteristics and anti-tumor activity of PARP inhibitor IMP4297 and temozolomide combination therapy in patients with advanced solid tumors and with ES-SCLC who develops disease progression after 1L platinum-based regimen.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| GenHarp Clinical Solutions | Evergreen Park, Illinois, United States | — |
| Gabrail Cancer Researh Center | Canton, Ohio, United States | — |
| Mark H. Zangmeister Center | Columbus, Ohio, United States | — |
| Sarah Cannon Research Institute - Tennessee Oncology | Tennessee City, Tennessee, United States | — |
| Border Medical Oncology | Albury, New South Wales, Australia | — |
| Blacktown Hospital | Blacktown, New South Wales, Australia | — |
| Orange Hospital | Orange, New South Wales, Australia | — |
| Peninsula Health Frankston Hospital | Frankston, Victoria, Australia | — |
| Beijing Cancer Hospital | Beijing, China | — |
| Jilin Cancer Hospital | Jilin City, China | — |
| Fudan University Shanghai Cancer Center | Shanghai, China | — |
| Hubei Cancer Hospital | Wuhan, China | — |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04434482